Morgan Stanley caused a stir on Tuesday when it put out a "bear case" scenario of $10. Now Citi is getting in on the act.Investingread more
Qualcomm unlawfully suppressed competition in the market for cellphone chips and used its dominant position to impose excessive licensing fees, a U.S. judged ruled.Technologyread more
Target's e-commerce sales also surged 42%, as shoppers increasingly turned to its curbside pickup service for online orders, something Amazon can't offer.Retailread more
Homeowners are taking advantage of lower interest rates, rushing to refinance their mortgages before rates potentially turn higher again.Real Estateread more
Lowe's shares plummeted 8% before the bell Wednesday after the company posted mixed fiscal first-quarter results and cut its forecast for the year, as higher costs weighed on...Retailread more
Department stores are being hung out to dry as Kohl's shares fall after earnings, but some experts still see opportunity in the space.Trading Nationread more
It may be years from visiting your neighborhood, but a walking robot is part of Ford's vision for how its autonomous vehicles will deliver packages.Technologyread more
Brazilian makeup brand Natura Cosmeticos agreed to buy Avon Products, according to two media reports early on Wednesday.Retailread more
Consumers in China are taking to social media to express their support for Huawei as the U.S. government looks to ramp up pressure on the Chinese smartphone maker.Technologyread more
Tensions between the two parties have heightened in recent months as the campaign for seats in the Brussels and Strasbourg-based parliament has crescendoed.Europe Politicsread more
St. Louis Federal Reserve President James Bullard expressed optimism that the United States and China will reach a deal to end their trade war.World Economyread more
The talk will be held at the AXA Equitable Center in Manhattan at 10 a.m. ET on Tuesday.
"We have hundreds of hours of internal video, Ackman told CNBC's Halftime Report. "We have some internal documents that were given to us by some employees."
"This will be the most important presentation that I have made in my career," he said. "We won't disappoint."
The hedge fund manager also invited Herbalife CEO Michael Johnson to attend the talk and "sit in the front row."
"The company is clearly panicking," Ackman said of Herbalife's recent Twitter campaign that called him the "Worst of Wall Street."
"These so-called nutritional clubs—places where people get together to talk about losing weight—that's not what's happening at these venues," he said.
Herbalife stock was down more than 6 percent after the interview.
"Herbalife is a company about great products and great company," said CFO John DeSimone in a statement. "We are proud of the tireless efforts of our millions of members around the world and know that their passion is what makes Herbalife the incredible company it is today."
DeSimone will be on CNBC at 9 a.m. ET on Tuesday.
Pershing Square is short on Herbalife and has climbed more than 25 percent during the first half of 2014 despite a rise in Herbalife's share price.
Last week, Ackman said he would love for activist investor Carl Icahn to sell his 17 million shares in Herbalife.
"That would be a great outcome for Carl, and that would be wonderful for us," Ackman said at the Delivering Alpha conference presented by CNBC and Institutional Investor.
Pharma deal ahead?
"As the deal spread narrows, people perceive the probability [of the deal] increasing," said Ackman, whose firm holds a nearly 10 percent stake in Allergan.
The spread on the deal—or the difference between the value of the two companies' shares and the ratio implied by the deal's terms—had dropped more than 50 basis points to below 3 percent on Monday.
"The quality of those earnings is not very high quality," the hedge fund manager said. "The growth in earnings that you're seeing here is not driven by an increase in revenue growth."
"Really what they're doing is cutting out fat they really could have cut out a long time ago," he told CNBC.
Ackman's Pershing Square and Valeant made a joint offer for Allergan in April, which the company has rejected. The fund will not raise its bid, Ackman said.
—By CNBC.com. Reuters contributed to this report.